Medical Dialogues
  • Dermatology
Login Register
This site is intended for healthcare professionals only
Login Register
  • MD Brand Connect
  • Vaccine Hub
  • MDTV
    • Breaking News
    • Medical News Today
    • Health News Today
    • Latest
    • Journal Club
    • Medico Legal Update
    • Latest Webinars
    • MD Shorts
    • Health Dialogues
  • Fact Check
  • Health Dialogues
Medical Dialogues
  • Medical News & Guidelines
      • Anesthesiology
      • Cardiology and CTVS
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endocrinology
      • ENT
      • Gastroenterology
      • Medicine
      • Nephrology
      • Neurology
      • Obstretics-Gynaecology
      • Oncology
      • Ophthalmology
      • Orthopaedics
      • Pediatrics-Neonatology
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
      • Laboratory Medicine
      • Diet
      • Nursing
      • Paramedical
      • Physiotherapy
  • Health news
      • Doctor News
      • Government Policies
      • Hospital & Diagnostics
      • International Health News
      • Medical Organization News
      • Medico Legal News
      • NBE News
      • NMC News
  • Fact Check
      • Bone Health Fact Check
      • Brain Health Fact Check
      • Cancer Related Fact Check
      • Child Care Fact Check
      • Dental and oral health fact check
      • Diabetes and metabolic health fact check
      • Diet and Nutrition Fact Check
      • Eye and ENT Care Fact Check
      • Fitness fact check
      • Gut health fact check
      • Heart health fact check
      • Kidney health fact check
      • Medical education fact check
      • Men's health fact check
      • Respiratory fact check
      • Skin and hair care fact check
      • Vaccine and Immunization fact check
      • Women's health fact check
  • AYUSH
    • Ayurveda
    • Homeopathy
    • Siddha
    • Unani
    • Yoga
  • State News
      • Andaman and Nicobar Islands
      • Andhra Pradesh
      • Arunachal Pradesh
      • Assam
      • Bihar
      • Chandigarh
      • Chattisgarh
      • Dadra and Nagar Haveli
      • Daman and Diu
      • Delhi
      • Goa
      • Gujarat
      • Haryana
      • Himachal Pradesh
      • Jammu & Kashmir
      • Jharkhand
      • Karnataka
      • Kerala
      • Ladakh
      • Lakshadweep
      • Madhya Pradesh
      • Maharashtra
      • Manipur
      • Meghalaya
      • Mizoram
      • Nagaland
      • Odisha
      • Puducherry
      • Punjab
      • Rajasthan
      • Sikkim
      • Tamil Nadu
      • Telangana
      • Tripura
      • Uttar Pradesh
      • Uttrakhand
      • West Bengal
  • Medical Education
      • Ayush Education News
      • Dentistry Education News
      • Medical Admission News
      • Medical Colleges News
      • Medical Courses News
      • Medical Universities News
      • Nursing education News
      • Paramedical Education News
      • Study Abroad
  • Industry
      • Health Investment News
      • Health Startup News
      • Medical Devices News
      • Pharma News
      • Pharmacy Education News
      • Industry Perspective
  • MDTV
      • Health Dialogues MDTV
      • Health News today MDTV
      • Latest Videos MDTV
      • Latest Webinars MDTV
      • MD shorts MDTV
      • Medical News Today MDTV
      • Medico Legal Update MDTV
      • Top Videos MDTV
      • Health Perspectives MDTV
      • Journal Club MDTV
      • Medical Dialogues Show
This site is intended for healthcare professionals only
LoginRegister
Medical Dialogues
LoginRegister
  • Home
  • Medical news & Guidelines
    • Anesthesiology
    • Cardiology and CTVS
    • Critical Care
    • Dentistry
    • Dermatology
    • Diabetes and Endocrinology
    • ENT
    • Gastroenterology
    • Medicine
    • Nephrology
    • Neurology
    • Obstretics-Gynaecology
    • Oncology
    • Ophthalmology
    • Orthopaedics
    • Pediatrics-Neonatology
    • Psychiatry
    • Pulmonology
    • Radiology
    • Surgery
    • Urology
    • Laboratory Medicine
    • Diet
    • Nursing
    • Paramedical
    • Physiotherapy
  • Health news
    • Doctor News
    • Government Policies
    • Hospital & Diagnostics
    • International Health News
    • Medical Organization News
    • Medico Legal News
    • NBE News
    • NMC News
  • Fact Check
    • Bone Health Fact Check
    • Brain Health Fact Check
    • Cancer Related Fact Check
    • Child Care Fact Check
    • Dental and oral health fact check
    • Diabetes and metabolic health fact check
    • Diet and Nutrition Fact Check
    • Eye and ENT Care Fact Check
    • Fitness fact check
    • Gut health fact check
    • Heart health fact check
    • Kidney health fact check
    • Medical education fact check
    • Men's health fact check
    • Respiratory fact check
    • Skin and hair care fact check
    • Vaccine and Immunization fact check
    • Women's health fact check
  • AYUSH
    • Ayurveda
      • Ayurveda Giuidelines
      • Ayurveda News
    • Homeopathy
      • Homeopathy Guidelines
      • Homeopathy News
    • Siddha
      • Siddha Guidelines
      • Siddha News
    • Unani
      • Unani Guidelines
      • Unani News
    • Yoga
      • Yoga Guidelines
      • Yoga News
  • State News
    • Andaman and Nicobar Islands
    • Andhra Pradesh
    • Arunachal Pradesh
    • Assam
    • Bihar
    • Chandigarh
    • Chattisgarh
    • Dadra and Nagar Haveli
    • Daman and Diu
    • Delhi
    • Goa
    • Gujarat
    • Haryana
    • Himachal Pradesh
    • Jammu & Kashmir
    • Jharkhand
    • Karnataka
    • Kerala
    • Ladakh
    • Lakshadweep
    • Madhya Pradesh
    • Maharashtra
    • Manipur
    • Meghalaya
    • Mizoram
    • Nagaland
    • Odisha
    • Puducherry
    • Punjab
    • Rajasthan
    • Sikkim
    • Tamil Nadu
    • Telangana
    • Tripura
    • Uttar Pradesh
    • Uttrakhand
    • West Bengal
  • Medical Education
    • Ayush Education News
    • Dentistry Education News
    • Medical Admission News
    • Medical Colleges News
    • Medical Courses News
    • Medical Universities News
    • Nursing education News
    • Paramedical Education News
    • Study Abroad
  • Industry
    • Health Investment News
    • Health Startup News
    • Medical Devices News
    • Pharma News
      • CDSCO (Central Drugs Standard Control Organisation) News
    • Pharmacy Education News
    • Industry Perspective
  • Home
  • Cardiology-CTVS
  • Cardiology & CTVS News
  • Dapagliflozin Shines...

Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings

Dr. Prem AggarwalWritten by Dr. Prem Aggarwal Published On 2025-07-02T11:01:56+05:30  |  Updated On 2 July 2025 4:32 PM IST
Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings
  • facebook
  • twitter
  • linkedin
  • whatsapp
  • Telegram
  • Email

Dapagliflozin reduced the risk of all-cause mortality or worsening heart failure by 28% in patients with aortic stenosis undergoing transcatheter aortic valve implantation (TAVI), a new study has reported.

The DapaTAVI trial, a multicenter randomized controlled study published in The New England Journal of Medicine, assessed dapagliflozin 10 mg once daily in 1222 high-risk patients undergoing TAVI across 39 centers in Spain. Participants had severe aortic stenosis, prior heart failure, and at least one additional risk factor—moderate renal impairment (eGFR 25–75 ml/min/1.73 m²), type 2 diabetes, or LVEF ≤40%; the mean age was 82.4 years, with 72% aged ≥80 years. The primary endpoint was a composite of all-cause mortality or worsening heart failure at one year. The trial’s primary endpoint was a composite of all-cause mortality or worsening heart failure (hospitalization or urgent visits requiring IV diuretics) at one-year follow-up.

Key findings of the study include

At one year, dapagliflozin reduced the primary composite outcome of all-cause mortality or worsening heart failure by 28% relative risk reduction (15.0% dapagliflozin vs 20.1% standard care; HR 0.72; 95% CI, 0.55–0.95; P = 0.02).


Figure: Kaplan–Meier curve showing time to primary composite outcome (death or worsening of heart failure) post-TAVI.Adapted from Raposeiras-Roubín S, et al. Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation. N Engl J Med. 2025; DOI: 10.1056/NEJMoa2500366.

Worsening heart failure was reduced by 37% (9.4% vs 14.4%; subHR 0.63; 95% CI, 0.45–0.88), hospitalizations for heart failure by 32% (7.4% vs 10.7%; subHR 0.68; 95% CI, 0.46–0.99), and urgent heart failure visits requiring IV diuretics by 54% (2.8% vs 6.0%; subHR 0.46; 95% CI, 0.26–0.82).

Dapagliflozin also reduced the secondary outcome of cardiovascular death or heart failure hospitalization by 29% (10.1% vs 13.8%; subHR 0.71; 95% CI, 0.51–0.98). The total number of recurrent events—cardiovascular deaths and heart failure hospitalizations—was reduced by 33% (79 vs 121 events; rate ratio 0.67; 95% CI, 0.47–0.95).

A prespecified subgroup analysis was performed to assess the consistency of treatment effect, with key results summarized below.

Benefit in Patients with CV Risk Factors: In patients with type 2 diabetes, dapagliflozin reduced the primary outcome by 33% (15.2% vs 22.7%; HR, 0.63; 95% CI, 0.42–0.94). In those with hypertension, the primary endpoint outcome reduction was 24% (15.3% vs 20.2%; HR 0.73; 95% CI, 0.54–0.97).

Outcome in Patients with Cardiac Co-Morbidities: In patients with preserved left ventricular ejection fraction (LVEF >40%), dapagliflozin reduced primary outcome by 33% (14.1% vs 21.2%; HR 0.67; 95% CI, 0.50–0.91). Those with mild or no left ventricular hypertrophy also benefited, with a 29% event reduction (11.8% vs 16.1%; HR 0.72; 95% CI, 0.52–1.00).

Patients with atrial fibrillation had a 33% relative risk reduction (19.6% vs 29.2%; HR 0.63; 95% CI, 0.44–0.90).

Renal Function: In patients with impaired renal function (eGFR <60 ml/min/1.73 m²), dapagliflozin reduced primary outcome by 28% (17.3% vs 22.9%; HR 0.71; 95% CI, 0.49–1.03). Among those with preserved kidney function (eGFR ≥60), the risk was reduced by 26% (12.7% vs 17.3%; HR 0.72; 95% CI, 0.45–1.16).

Background Cardiovascular Therapy: Dapagliflozin reduced the composite outcome of death or worsening heart failure by 30% in patients receiving RAS inhibitors (12.4% vs 17.6%; HR 0.68; 95% CI, 0.47–0.99). While not statistically significant, similar trends were observed in patients on beta-blockers (19.2% vs 24.9%; HR 0.74; 95% CI, 0.50–1.10) and diuretics (16.8% vs 21.6%; HR 0.75; 95% CI, 0.56–1.02), indicating a consistent treatment effect across therapies.

The results of DapaTAVI trial highlight a promising role for the SGLT2 inhibitor, dapagliflozin, in patients undergoing TAVI, particularly those with coexisting heart failure or renal dysfunction.

Reference: Díez-Villanueva, Pablo, et al. “Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation.” The New England Journal of Medicine, vol. 390, no. 13, 2025, pp. 1234–1245. DOI: 10.1056/NEJMoa2500366.

Abbreviations: TAVI – Transcatheter Aortic Valve Implantation, DapaTAVI – Dapagliflozin in Patients Undergoing Transcatheter Aortic Valve Implantation, HR – Hazard Ratio, subHR – Subdistribution Hazard Ratio, CI – Confidence Interval, eGFR – Estimated Glomerular Filtration Rate, LVEF – Left Ventricular Ejection Fraction, IV – Intravenous, SGLT2 – Sodium-Glucose Cotransporter 2, RAS – Renin-Angiotensin System

dapatavidapa tavi trialtavipcidapagliflozindapagliflozin efficacypost tavi patientsnejmtype 2 diabetest2doxraaortic stenosisheart failuredapagliflozin heart failuretranscatheter aortic valve implantationdapatavi trial
Dr. Prem Aggarwal
Dr. Prem Aggarwal

Dr Prem Aggarwal, (MD Medicine, DNB Cardiology) is a Cardiologist by profession and also the Co-founder and Chairman of Medical Dialogues. He focuses on news and perspectives about cardiology, and medicine related developments at Medical Dialogues. He can be reached out at drprem@medicaldialogues.in

Show Full Article
Next Story

Editorial

Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings

Dapagliflozin Shines in Post-TAVI Patients:DAPA-TAVI Trial Findings

Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension, Dyslipidemia, and Familial ASCVD Risk

Identifying Candidates for Aspirin in Primary Prevention: Men Aged 40-50 with Hypertension,...

Featured image representing thinking

Is Pharma Marketing Going Through "Thinking Recession"?

Beyond BMI: Why Pioglitazone Deserves a Place in Managing Thin-Fat Type 2 Diabetes in India

Beyond BMI: Why Pioglitazone Deserves a Place in Managing 'Thin-Fat' Type 2 Diabetes in India

How to Improve Adherence in Hypertensive Patients? Bridging the Gap with CONNECT Tool

How to Improve Adherence in Hypertensive Patients? Bridging the Gap with CONNECT Tool

View All

Journal Club Today

Early Bedtimes May Boost Physical Activity: Study Finds

Early Bedtimes May Boost Physical Activity: Study Finds

View All

Health News Today

Health Bulletin 2/July/ 2025

Health Bulletin 2/July/ 2025

View All
© 2022 All Rights Reserved.
Powered By: Hocalwire
X
We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok